| Citation: |
SUI Daxing, WANG Xueying, ZHANG Jiaxin. A New N-staging System for Predicting Postoperative Survival of M0 Stage Inflammatory Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(8): 799-805. DOI: 10.3971/j.issn.1000-8578.2022.21.1532
|
To establish a new N-stage system combining the number of metastatic lymph nodes and the ratio of metastatic lymph nodes for postoperative M0 stage inflammatory breast cancer patients.
Based on the data of inflammatory breast cancer patients in the SEER database, the number of metastatic lymph nodes and the ratio of metastatic lymph nodes were calculated.A new N-staging system was established and compared with the 8th edition of AJCC TNM staging system of breast cancer.The nomograph prognostic model was constructed and validated.
The prediction performance of the new N-staging system for postoperative survival of M0 inflammatory breast cancer patients was better than the traditional N-staging system.The nomograph prognostic model showed an excellent clinical efficacy with a consistency index of 0.711.
The new N-staging system has good predictive performance for postoperative survival of M0 inflammatory breast cancer patients and can accurately reflect the prognosis.
| [1] |
Fouad TM, Kogawa T, Liu DD, et al. Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis[J]. Breast Cancer Res Treat, 2015, 152(2): 407-416. doi: 10.1007/s10549-015-3436-x
|
| [2] |
Devi GR, Hough H, Barrett N, et al. Perspectives on Inflammatory Breast Cancer (IBC) Research, Clinical Management and Community Engagement from the Duke IBC Consortium[J]. J Cancer, 2019, 10(15): 3344-3351. doi: 10.7150/jca.31176
|
| [3] |
Arias-Pulido H, Cimino-Mathews AM, Chaher N, et al. Differential effects of CD20+ B cells and PD-L1+ immune cells on pathologic complete response and outcome: comparison between inflammatory breast cancer and locally advanced breast cancer patients[J]. Breast Cancer Res Treat, 2021, 190(3): 477-489. doi: 10.1007/s10549-021-06391-5
|
| [4] |
Cserni G, Chmielik E, Cserni B, et al. The new TNM-based staging of breast cancer[J]. Virchows Arch, 2018, 472(5): 697-703. doi: 10.1007/s00428-018-2301-9
|
| [5] |
Kinoshita T, Goto T. Links between Inflammation and Postoperative Cancer Recurrence[J]. J Clin Med, 2021, 10(2): 228. doi: 10.3390/jcm10020228
|
| [6] |
Kida K, Hess KR, Lim B, et al. Validation of Prognostic Stage and Anatomic Stage in the American Joint Committee on Cancer 8th Edition for Inflammatory Breast Cancer[J]. Cancers (Basel), 2020, 12(11): 3105. doi: 10.3390/cancers12113105
|
| [7] |
Wang Z, Wang H, Ding X, et al. A large-cohort retrospective study of metastatic patterns and prognostic outcomes between inflammatory and non-inflammatory breast cancer[J]. Ther Adv Med Oncol, 2020, 12: 1758835920932674.
|
| [8] |
Liu C, Li H, Zhuo R, et al. Grade-lymph node ratio predicts the survival of breast cancer in different molecular types: A surveillance, epidemiology, and end results population-based analysis[J]. Medicine (Baltimore), 2019, 98(28): e16436. doi: 10.1097/MD.0000000000016436
|
| [9] |
Oven Ustaalioglu BB, Bilici A, Kefeli U, et al. Does the metastatic lymph node ratio influence the disease-free survival of patients with breast cancer: single-center experiences[J]. Oncology, 2010, 79(1-2): 105-111. doi: 10.1159/000320162
|
| [10] |
Wecsler JS, Tereffe W, Pedersen RC, et al. Lymph node status in inflammatory breast cancer[J]. Breast Cancer Res Treat, 2015, 151(1): 113-120. doi: 10.1007/s10549-015-3367-6
|
| [11] |
Rosso KJ, Tadros AB, Weiss A, et al. Improved Locoregional Control in a Contemporary Cohort of Nonmetastatic Inflammatory Breast Cancer Patients Undergoing Surgery[J]. Ann Surg Oncol, 2017, 24(10): 2981-2988. doi: 10.1245/s10434-017-5952-x
|
| [12] |
Mamouch F, Berrada N, Aoullay Z, et al. Inflammatory Breast Cancer: A Literature Review[J]. World J Oncol, 2018, 9(5-6): 129-135. doi: 10.14740/wjon1161
|
| [13] |
Adesoye T, Lucci A. Current Surgical Management of Inflammatory Breast Cancer[J]. Ann Surg Oncol, 2021, 28(10): 5461-5467. doi: 10.1245/s10434-021-10522-z
|
| [14] |
Fouad TM, Barrera AMG, Reuben JM, et al. Inflammatory breast cancer: a proposed conceptual shift in the UICC-AJCC TNM staging system[J]. Lancet Oncol, 2017, 18(4): e228-e232. doi: 10.1016/S1470-2045(17)30192-4
|
| [15] |
Schairer C, Hablas A, Eldein IAS, et al. Clinico-pathologic and mammographic characteristics of inflammatory and non-inflammatory breast cancer at six centers in North Africa[J]. Breast Cancer Res Treat, 2019, 176(2): 407-417. doi: 10.1007/s10549-019-05237-5
|
| [16] |
Bertucci F, Rypens C, Finetti P, et al. NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers[J]. Mol Oncol, 2020, 14(3): 504-519. doi: 10.1002/1878-0261.12621
|
| [17] |
Li J, Gonzalez-Angulo AM, Allen PK, et al. Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer[J]. Oncologist, 2011, 16(12): 1675-1683. doi: 10.1634/theoncologist.2011-0196
|
| [18] |
Rueth NM, Lin HY, Bedrosian I, et al. Underuse of trimodality treatment affects survival for patients with inflammatory breast cancer: an analysis of treatment and survival trends from the National Cancer Database[J]. J Clin Oncol, 2014, 32(19): 2018-2024. doi: 10.1200/JCO.2014.55.1978
|
Figures(8) / Tables(3)
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: